Verseau Therapeutics, Inc, based in Bedford, MA, is a pioneering biotechnology company focused on revolutionizing cancer treatment through the repolarization of macrophages. By stimulating the conversion of immuno-suppressive M2 macrophages into pro-inflammatory M1 macrophages, Verseau aims to induce a coordinated immune response to combat cancer.
With their proprietary human-based discovery engine, Verseau has successfully identified and validated over 20 targets for regulating macrophage biology. Their two lead programs, targeting PSGL-1 and VSIG4, are rapidly progressing towards clinical development, offering promising advancements in the field of cancer immunotherapy.
Generated from the website